| Parameters . | RBC− Group (n = 1478) . | RBC+ Group (n = 1528) . | P value . |
|---|---|---|---|
| Age (years) | 62 (56;71) | 69 (61;74) | <0.001 |
| Gender, males (%) | 93.2 | 81.2 | <0.001 |
| Body weight (kg) | 88 (80;98) | 83 (75;93) | <0.001 |
| Body height (m) | 1.75 (1.70;1.80) | 1.73 (1.68;1.78) | <0.001 |
| Body surface area (m2) | 2.06 (1.95;2.20) | 2.00 (1.90;2.10) | <0.001 |
| Haematocrit (%) | 43.4 (40.9;45.6) | 41.2 (38.7;43.6) | <0.001 |
| Left ventricular ejection fraction (%) | 60 (55;65) | 60 (50;65) | <0.001 |
| EuroSCORE (logistic) | 1.8 (1.1;2.9) | 2.7 (1.6;4.7) | <0.001 |
| Smoker (%) | 50.5 | 41.6 | <0.001 |
| Diabetes mellitus (%) | 30.9 | 33.1 | 0.214 |
| Haemofiltration (%) | 0.0 | 0.2 | >0.999 |
| Stroke (%) | 2.7 | 2.8 | 0.912 |
| Myocardial infarction (%) | 26.6 | 29.9 | 0.044 |
| Chronic obstructive pulmonary disease (%) | 2.1 | 1.8 | 0.246 |
| Redo (%) | 2.9 | 4.7 | 0.063 |
| Vessel diseases (n) | 3 (2;3) | 3 (3;3) | <0.001 |
| Peripheral arterial occlusive disease (%) | 8.3 | 10.2 | 0.160 |
| NYHA Class > II (%) | 32.3 | 41.5 | <0.001 |
| Operation priority, urgent/emergent (%) | 8.2 | 10.7 | 0.092 |
| eGFR (ml/min/1.73 m2) | 85.4 (71.8;98.2) | 80.2 (65.4;93.0) | <0.001 |
| Medications | |||
| β-Blockers (%) | 72.0 | 73.0 | 0.542 |
| ACE inhibitors/AT-blockers (%) | 62.3 | 64.9 | 0.141 |
| Nitrates, intravenous (%) | 3.3 | 3.0 | 0.757 |
| Aspirin (%) | 76.3 | 72.8 | 0.027 |
| Clopidogrel (%) | 12.3 | 14.1 | 0.133 |
| Ticlopidin (%) | 0.3 | 0.3 | 0.751 |
| Off-pump surgery (%) | 78.8 | 65.3 | <0.001 |
| Parameters . | RBC− Group (n = 1478) . | RBC+ Group (n = 1528) . | P value . |
|---|---|---|---|
| Age (years) | 62 (56;71) | 69 (61;74) | <0.001 |
| Gender, males (%) | 93.2 | 81.2 | <0.001 |
| Body weight (kg) | 88 (80;98) | 83 (75;93) | <0.001 |
| Body height (m) | 1.75 (1.70;1.80) | 1.73 (1.68;1.78) | <0.001 |
| Body surface area (m2) | 2.06 (1.95;2.20) | 2.00 (1.90;2.10) | <0.001 |
| Haematocrit (%) | 43.4 (40.9;45.6) | 41.2 (38.7;43.6) | <0.001 |
| Left ventricular ejection fraction (%) | 60 (55;65) | 60 (50;65) | <0.001 |
| EuroSCORE (logistic) | 1.8 (1.1;2.9) | 2.7 (1.6;4.7) | <0.001 |
| Smoker (%) | 50.5 | 41.6 | <0.001 |
| Diabetes mellitus (%) | 30.9 | 33.1 | 0.214 |
| Haemofiltration (%) | 0.0 | 0.2 | >0.999 |
| Stroke (%) | 2.7 | 2.8 | 0.912 |
| Myocardial infarction (%) | 26.6 | 29.9 | 0.044 |
| Chronic obstructive pulmonary disease (%) | 2.1 | 1.8 | 0.246 |
| Redo (%) | 2.9 | 4.7 | 0.063 |
| Vessel diseases (n) | 3 (2;3) | 3 (3;3) | <0.001 |
| Peripheral arterial occlusive disease (%) | 8.3 | 10.2 | 0.160 |
| NYHA Class > II (%) | 32.3 | 41.5 | <0.001 |
| Operation priority, urgent/emergent (%) | 8.2 | 10.7 | 0.092 |
| eGFR (ml/min/1.73 m2) | 85.4 (71.8;98.2) | 80.2 (65.4;93.0) | <0.001 |
| Medications | |||
| β-Blockers (%) | 72.0 | 73.0 | 0.542 |
| ACE inhibitors/AT-blockers (%) | 62.3 | 64.9 | 0.141 |
| Nitrates, intravenous (%) | 3.3 | 3.0 | 0.757 |
| Aspirin (%) | 76.3 | 72.8 | 0.027 |
| Clopidogrel (%) | 12.3 | 14.1 | 0.133 |
| Ticlopidin (%) | 0.3 | 0.3 | 0.751 |
| Off-pump surgery (%) | 78.8 | 65.3 | <0.001 |
RBC: red blood cells; NYHA: New York Heart Association; eGFR: estimated glomerular filtration rate; ACE: angiotensin-converting enzyme; AT: angiotensin.
| Parameters . | RBC− Group (n = 1478) . | RBC+ Group (n = 1528) . | P value . |
|---|---|---|---|
| Age (years) | 62 (56;71) | 69 (61;74) | <0.001 |
| Gender, males (%) | 93.2 | 81.2 | <0.001 |
| Body weight (kg) | 88 (80;98) | 83 (75;93) | <0.001 |
| Body height (m) | 1.75 (1.70;1.80) | 1.73 (1.68;1.78) | <0.001 |
| Body surface area (m2) | 2.06 (1.95;2.20) | 2.00 (1.90;2.10) | <0.001 |
| Haematocrit (%) | 43.4 (40.9;45.6) | 41.2 (38.7;43.6) | <0.001 |
| Left ventricular ejection fraction (%) | 60 (55;65) | 60 (50;65) | <0.001 |
| EuroSCORE (logistic) | 1.8 (1.1;2.9) | 2.7 (1.6;4.7) | <0.001 |
| Smoker (%) | 50.5 | 41.6 | <0.001 |
| Diabetes mellitus (%) | 30.9 | 33.1 | 0.214 |
| Haemofiltration (%) | 0.0 | 0.2 | >0.999 |
| Stroke (%) | 2.7 | 2.8 | 0.912 |
| Myocardial infarction (%) | 26.6 | 29.9 | 0.044 |
| Chronic obstructive pulmonary disease (%) | 2.1 | 1.8 | 0.246 |
| Redo (%) | 2.9 | 4.7 | 0.063 |
| Vessel diseases (n) | 3 (2;3) | 3 (3;3) | <0.001 |
| Peripheral arterial occlusive disease (%) | 8.3 | 10.2 | 0.160 |
| NYHA Class > II (%) | 32.3 | 41.5 | <0.001 |
| Operation priority, urgent/emergent (%) | 8.2 | 10.7 | 0.092 |
| eGFR (ml/min/1.73 m2) | 85.4 (71.8;98.2) | 80.2 (65.4;93.0) | <0.001 |
| Medications | |||
| β-Blockers (%) | 72.0 | 73.0 | 0.542 |
| ACE inhibitors/AT-blockers (%) | 62.3 | 64.9 | 0.141 |
| Nitrates, intravenous (%) | 3.3 | 3.0 | 0.757 |
| Aspirin (%) | 76.3 | 72.8 | 0.027 |
| Clopidogrel (%) | 12.3 | 14.1 | 0.133 |
| Ticlopidin (%) | 0.3 | 0.3 | 0.751 |
| Off-pump surgery (%) | 78.8 | 65.3 | <0.001 |
| Parameters . | RBC− Group (n = 1478) . | RBC+ Group (n = 1528) . | P value . |
|---|---|---|---|
| Age (years) | 62 (56;71) | 69 (61;74) | <0.001 |
| Gender, males (%) | 93.2 | 81.2 | <0.001 |
| Body weight (kg) | 88 (80;98) | 83 (75;93) | <0.001 |
| Body height (m) | 1.75 (1.70;1.80) | 1.73 (1.68;1.78) | <0.001 |
| Body surface area (m2) | 2.06 (1.95;2.20) | 2.00 (1.90;2.10) | <0.001 |
| Haematocrit (%) | 43.4 (40.9;45.6) | 41.2 (38.7;43.6) | <0.001 |
| Left ventricular ejection fraction (%) | 60 (55;65) | 60 (50;65) | <0.001 |
| EuroSCORE (logistic) | 1.8 (1.1;2.9) | 2.7 (1.6;4.7) | <0.001 |
| Smoker (%) | 50.5 | 41.6 | <0.001 |
| Diabetes mellitus (%) | 30.9 | 33.1 | 0.214 |
| Haemofiltration (%) | 0.0 | 0.2 | >0.999 |
| Stroke (%) | 2.7 | 2.8 | 0.912 |
| Myocardial infarction (%) | 26.6 | 29.9 | 0.044 |
| Chronic obstructive pulmonary disease (%) | 2.1 | 1.8 | 0.246 |
| Redo (%) | 2.9 | 4.7 | 0.063 |
| Vessel diseases (n) | 3 (2;3) | 3 (3;3) | <0.001 |
| Peripheral arterial occlusive disease (%) | 8.3 | 10.2 | 0.160 |
| NYHA Class > II (%) | 32.3 | 41.5 | <0.001 |
| Operation priority, urgent/emergent (%) | 8.2 | 10.7 | 0.092 |
| eGFR (ml/min/1.73 m2) | 85.4 (71.8;98.2) | 80.2 (65.4;93.0) | <0.001 |
| Medications | |||
| β-Blockers (%) | 72.0 | 73.0 | 0.542 |
| ACE inhibitors/AT-blockers (%) | 62.3 | 64.9 | 0.141 |
| Nitrates, intravenous (%) | 3.3 | 3.0 | 0.757 |
| Aspirin (%) | 76.3 | 72.8 | 0.027 |
| Clopidogrel (%) | 12.3 | 14.1 | 0.133 |
| Ticlopidin (%) | 0.3 | 0.3 | 0.751 |
| Off-pump surgery (%) | 78.8 | 65.3 | <0.001 |
RBC: red blood cells; NYHA: New York Heart Association; eGFR: estimated glomerular filtration rate; ACE: angiotensin-converting enzyme; AT: angiotensin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
